K4894
Poloxamer 188
solid
Synonym(s):
Poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol), Lutrol F68
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Quality Level
agency
USP/NF, meets USP testing specifications
form
solid
mol wt
8.400 g/mol
pH
5.0-7.5(2.5% solution)
application(s)
sample preservation
SMILES string
O2C(C2)C.O1CC1
InChI
1S/C3H6O.C2H4O/c1-3-2-4-3;1-2-3-1/h3H,2H2,1H3;1-2H2
InChI key
RVGRUAULSDPKGF-UHFFFAOYSA-N
General description
Poloxamer 188 is a non-ionic amphiphilic copolymer, which has a central chain of hydrophobic polyoxypropylene and a hydrophilic polyoxyethylene at the ends.
Application
Poloxamer 188 has been used as a supplement in F17 medium for the culture of HEK293-6E cells. It has also been used as a component of flow cytometry (FACS) buffer as a non-ionic detergent that protects cells from hydrodynamic damage.
Poloxamer 188 has been used as a component of cell-dissociation/minimal essential media (MEM) to sort tumor cells using EpCAM antibody-conjugated magnetic beads.
Biochem/physiol Actions
Poloxamer 188 exhibits cytoprotective, hemorheological, anti-inflammatory, antithrombotic activities. It maintains the stability of membrane barrier function. P188 lowers surface tension and hydrophobic-based cellular adherence. It also inhibits lipid peroxidation stimulated by Fe2+ and H2O2.
Legal Information
Still not finding the right product?
Explore all of our products under Poloxamer 188
Storage Class
11 - Combustible Solids
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
S Dhara et al.
Nature communications, 12(1), 3044-3044 (2021-05-26)
Unlike other malignancies, therapeutic options in pancreatic ductal adenocarcinoma (PDAC) are largely limited to cytotoxic chemotherapy without the benefit of molecular markers predicting response. Here we report tumor-cell-intrinsic chromatin accessibility patterns of treatment-naïve surgically resected PDAC tumors that were subsequently
Antibody humanization by molecular dynamics simulations?in-silico guided selection of critical backmutations
Christian Margretter
Journal of Molecular Recognition (2016)
S Dhara et al.
Nature communications, 12(1), 3044-3044 (2021-05-26)
Unlike other malignancies, therapeutic options in pancreatic ductal adenocarcinoma (PDAC) are largely limited to cytotoxic chemotherapy without the benefit of molecular markers predicting response. Here we report tumor-cell-intrinsic chromatin accessibility patterns of treatment-naïve surgically resected PDAC tumors that were subsequently